| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 | 3060 | 2013 |
| Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial AD Roth, S Tejpar, M Delorenzi, P Yan, R Fiocca, D Klingbiel, D Dietrich, ... J Clin Oncol 28 (3), 466-474, 2010 | 1431 | 2010 |
| Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 E Van Cutsem, R Labianca, G Bodoky, C Barone, E Aranda, B Nordlinger, ... J Clin Oncol 27 (19), 3117-3125, 2009 | 606 | 2009 |
| Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with … M Dank, J Zaluski, C Barone, V Valvere, S Yalcin, C Peschel, M Wenczl, ... Annals of oncology 19 (8), 1450-1457, 2008 | 453 | 2008 |
| Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients C Pozzo, M Basso, A Cassano, M Quirino, G Schinzari, N Trigila, ... Annals of Oncology 15 (6), 933-939, 2004 | 418 | 2004 |
| Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab A Sartore-Bianchi, M Moroni, S Veronese, C Carnaghi, E Bajetta, G Luppi, ... Journal of Clinical Oncology 25 (22), 3238-3245, 2007 | 401 | 2007 |
| Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study M Muscaritoli, S Lucia, A Farcomeni, V Lorusso, V Saracino, C Barone, ... Oncotarget 8 (45), 79884, 2017 | 392 | 2017 |
| Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical … C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ... JAMA oncology 5 (3), 343-350, 2019 | 353 | 2019 |
| Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a … J Tabernero, HJ Lenz, S Siena, A Sobrero, A Falcone, M Ychou, ... The Lancet Oncology 16 (8), 937-948, 2015 | 338 | 2015 |
| Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study JP Spano, C Chodkiewicz, J Maurel, R Wong, H Wasan, C Barone, ... The Lancet 371 (9630), 2101-2108, 2008 | 296 | 2008 |
| Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study CJA Punt, A Nagy, JY Douillard, A Figer, T Skovsgaard, J Monson, ... The Lancet 360 (9334), 671-677, 2002 | 270 | 2002 |
| Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a … C Pozzo, C Barone, J Szanto, E Padi, C Peschel, J Bükki, V Gorbunova, ... Annals of Oncology 15 (12), 1773-1781, 2004 | 229 | 2004 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 227 | 2019 |
| Inhibition of endogenous reverse transcriptase antagonizes human tumor growth I Sciamanna, M Landriscina, C Pittoggi, M Quirino, C Mearelli, R Beraldi, ... Oncogene 24 (24), 3923-3931, 2005 | 224 | 2005 |
| A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer M Aglietta, C Barone, MB Sawyer, MJ Moore, WH Miller Jr, C Bagalà, ... Annals of oncology 25 (9), 1750-1755, 2014 | 222 | 2014 |
| Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) C Pinto, F Di Fabio, C Barone, S Siena, A Falcone, S Cascinu, ... British journal of cancer 101 (8), 1261-1268, 2009 | 213 | 2009 |
| Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind … D Soulières, S Faivre, R Mesía, É Remenár, SH Li, A Karpenko, ... The Lancet Oncology 18 (3), 323-335, 2017 | 207 | 2017 |
| Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic … P Rougier, H Riess, R Manges, P Karasek, Y Humblet, C Barone, ... European journal of cancer 49 (12), 2633-2642, 2013 | 207 | 2013 |
| Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results … C Cremolini, F Loupakis, C Antoniotti, S Lonardi, G Masi, L Salvatore, ... Annals of oncology 26 (6), 1188-1194, 2015 | 189 | 2015 |
| Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases C Barone, G Nuzzo, A Cassano, M Basso, G Schinzari, F Giuliante, ... British journal of cancer 97 (8), 1035-1039, 2007 | 155 | 2007 |
